Terri Lipman, PhD, FAAN, CRNP, the Miriam Stirl Endowed Term Professor of Nutrition and Assistant Dean for Community Engagement, will be transitioning on June 30, 2022, after an incredible 33 years of service to the University and School. Terri has held a clinical practice in the Division of Endocrinology and Diabetes at the Children’s Hospital of Philadelphia and has been a strong voice for nurses and children in her service to the School, the University, and our West Philadelphia community.
Advancements in diabetes technology have improved quality of life and glycemic control in children with type 1 diabetes. However, data show that a subset of children is being left behind. Those from low-income families and non-Hispanic Black (NHB) children are not experiencing benefits associated with technological advances, and are at higher risk for diabetes complications and adverse outcomes through ongoing poor glycemic control.
Type 1 diabetes (T1D) is the third most common pediatric chronic disease in the United States, and the risk of the disease has risen sharply in non-Hispanic Black (NHB) children in the last 20 years, data show. Ironically, the significant advances in T1D therapeutics over recent years, especially new technologies, may have exacerbated racial disparities in diabetes treatment and outcomes.
Insulin pumps are widely used in the management of type 1 diabetes (T1D) and reviews have shown insulin pump therapy to be associated with improved glycemic control, fewer severe hypoglycemia events, and improved quality of life. Yet, non-Hispanic white children (NHW) are more than twice as likely as non-Hispanic Black children (NHB) to use this technology.
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM). The challenges of managing multiple doses of daily insulin administration, blood glucose monitoring, dietary and exercise requirements, can make self-care difficult and complicate outcomes. Adolescents with T1DM often have poorer diabetes outcomes than others, indicating that glucose control is difficult for them to maintain.
Faculty—both in their teaching and their research—are an increasingly vital link between nursing and social justice.
There are ways you could try to quantify the reach and influence of Penn Nursing. You could look at school rankings, which for the past five years have placed the School in the number one spot in the world. Or you could calculate the amount of research funding it’s been awarded by the National Institutes of Health.
The numbers are impressive. More than 4,300 generous donors. Over 13,400 gifts made. And in the end, Penn Nursing’s Innovating for Life and Living Campaign—part of Penn’s larger Power of Penn Campaign—raised $3 million more than its $60 million goal thanks to its Board of Advisors, lead volunteers, and many donors and friends.
How Penn Nursing is helping to get an accurate count— and why it matters.
Dear Colleagues – It feels like some time since I’ve been able to say this, but …Welcome back to Fagin Hall! It is great to be together again in our home base on Penn campus—and to resume in-person operations. It is my pleasure and privilege to welcome our returning students, faculty, and staff to this new academic year. I’d also like to welcome Penn Nursing’s new additions: 100 BSN, 83 ABSN, 65 MSN, 22 Post-MSN, 10 PhD, 41 Post-Masters DNP and executive leadership, and 28 Nurse Anesthesia DNP students. We have been waiting for you! Our faculty and staff have worked tirelessly to provide the best and safest educational experience possible.